SAI Parenteral Acquires Majority Stake in Noumed Pharmaceuticals for Strategic Expansion

SAI Parenteral has acquired a majority stake in Australia's Noumed Pharmaceuticals for Rs 125 crore. Noumed, a prominent supplier of OTC products, is set to open an advanced manufacturing facility in Adelaide. The acquisition enhances SAI's market presence and product portfolio, boosting its entry into global pharmaceutical markets.

In a significant move towards global expansion, diversified pharmaceutical company SAI Parenteral announced its acquisition of a majority stake in Australian company Noumed Pharmaceuticals for Rs 125 crore on Monday.

Noumed Pharmaceuticals, based in Adelaide, is recognized for its supply of private label over-the-counter (OTC) products to pharmacy chains across Australia and New Zealand. The company reports AUD 60 million in revenue and is investing AUD 53 million in a cutting-edge manufacturing facility in Adelaide, expected to commence operations by CY 2026's fourth quarter.

This acquisition is hailed by SAI Parenteral as a transformative step, promising to enhance their R&D capabilities and distribution network, as well as to leverage Noumed's extensive dossier library and upcoming manufacturing facility. This collaboration is set to expand SAI's reach into semi-regulated and regulated markets, ultimately creating long-term value for stakeholders.

(With inputs from agencies.)